|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsors and Collaborators: |
Mahidol University Thailand Research Fund |
| Information provided by: | Mahidol University |
| ClinicalTrials.gov Identifier: | NCT00592566 |
Purpose
Background: Pulmonary involvement in leptospirosis has been reported to be on the increase and is emerging as the main cause of death due to leptospirosis in many countries, including Thailand.
Methods: A prospective randomized controlled trial of desmopressin or high dose dexamethasone as adjunctive therapy in patients with suspected pulmonary hemorrhage associated with leptospirosis was conducted between July 2003 and October 2006 at 5 hospitals in Thailand.
| Condition | Intervention | Phase |
|
Leptospirosis |
Drug: Dexamethasone, desmopressin |
Phase II Phase III |
| ChemIDplus related topics: | Dexamethasone Dexamethasone acetate Dexamethasone Sodium Phosphate Doxiproct plus Sodium chloride Desmopressin Desmopressin acetate |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Open Label, Placebo Control, Parallel Assignment, Safety/Efficacy Study |
| Official Title: | An Open Randomized Controlled Trial of Desmopressin, and Dexamethasone as Adjunctive Therapy in Patients With Pulmonary Hemorrhage Associated With Leptospirosis |
| Enrollment: | 64 |
| Study Start Date: | July 2003 |
| Study Completion Date: | October 2006 |
| Primary Completion Date: | October 2006 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|
1: No Intervention
Standard supportive care
|
|
|
2: Experimental
Dexamethasone treatment
|
Drug: Dexamethasone, desmopressin
200 mg of dexamethasone IV infusion OD for 3 days or 0.3 microgram/ kg of desmopressin in 50 ml of saline, as a 30- minute infusion
|
|
3: Experimental
Desmopressin treatment
|
Drug: Dexamethasone, desmopressin
200 mg of dexamethasone IV infusion OD for 3 days or 0.3 microgram/ kg of desmopressin in 50 ml of saline, as a 30- minute infusion
|
Eligibility
| Ages Eligible for Study: | 15 Years to 90 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| Thailand, Loei Province | |||||
| Loei Hospital | |||||
| Mueng, Loei Province, Thailand, 45000 | |||||
| Mahidol University |
| Thailand Research Fund |
| Principal Investigator: | Kanigar Niwattayakul, MD | Loei Hospital, Loei, Thailand: |
| Study Chair: | Yupin Suputtamongkol, MD | Mahidol University, Thailand: |
More Information
| Responsible Party: | Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand ( Prof. Yupin Suputtamongkol ) |
| Study ID Numbers: | DDP2003, RDG4630213 |
| First Received: | January 1, 2008 |
| Last Updated: | January 11, 2008 |
| ClinicalTrials.gov Identifier: | NCT00592566 |
| Health Authority: | Thailand: Ethical Committee |
|
|
|
|
|